{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:24:00Z","timestamp":1791480240495,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004869","name":"Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the reliability, responsiveness, and validity of the\u00a0Scale for the Assessment and Rating of Ataxia (SARA) in patients with lysosomal storage disorders (LSDs) who present with neurological symptoms, and quantify the threshold for a clinically meaningful change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from three clinical trial cohorts (IB1001-201, IB1001-202, and IB1001-301) of patients with Niemann\u2013Pick disease type C (NPC) and GM2 Gangliosidoses (Tay\u2013Sachs and Sandhoff disease) comprising 122 patients and 703 visits. Reproducibility was described as re-test reliability between repeat baseline visits or baseline and post-treatment washout visits. Responsiveness was determined in relation to the Investigator\u2019s, Caregiver\u2019s, and Patient\u2019s Clinical Global Impression of Improvement (CGI-I). The CGI-I data was also used to quantify a threshold for a clinically meaningful improvement on the SARA scale. Using a qualitative methods approach, patient\/caregiver interviews from the IB1001-301 trial were further used to assess a threshold of meaningful change as well as the breadth of neurological signs and symptoms captured and evaluated by the SARA scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Inter-Class Correlation (ICC) was 0.95 or greater for all three trials, indicating a high internal consistency\/reliability. The mean change in SARA between repeat baseline and post-treatment washout visit assessments in all trials was \u22120.05, SD 1.98, i.e., minimal, indicating no significant differences, learning effects or other systematic biases. For the CGI-I responses and change in SARA scores, Area Under the Curve (AUC) values were 0.82, 0.71, and 0.77 for the Investigator\u2019s, Caregiver\u2019s, and Patient\u2019s CGI-I respectively, indicating strong agreement. Further qualitative analyses of the patient\/caregiver interviews demonstrated a 1-point or greater change on SARA to be a clinically meaningful improvement which is directly relevant to the patient\u2019s everyday functioning and quality of life. Changes captured by the SARA were also paralleled by improvement in a broad range of neurological signs and symptoms and beyond cerebellar ataxia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Qualitative and quantitative data demonstrate the reliability and responsiveness of the SARA score as a valid measure of neurological signs and symptoms in LSDs with CNS involvement, such as NPC and GM2 Gangliosidoses. A 1-point change represents a clinically meaningful transition reflecting the gain or loss of complex function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-024-12664-y","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T08:02:16Z","timestamp":1725350536000},"page":"6888-6902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2305-9948","authenticated-orcid":false,"given":"Julien","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Bremova-Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Brands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Foltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Arash-Kaps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Reichmannov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Rohrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasef","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyamini","family":"Sivananthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walterfarng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wibawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Martakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Manto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"12664_CR1","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717\u20131720. https:\/\/doi.org\/10.1212\/01.wnl.0000219042.60538.92","journal-title":"Neurology"},{"key":"12664_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1212\/WNL.0b013e3181d1a6c9","volume":"74","author":"T Schmitz-H\u00fcbsch","year":"2010","unstructured":"Schmitz-H\u00fcbsch T, Fimmers R, Rakowicz M et al (2010) Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74:678\u2013684. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d1a6c9","journal-title":"Neurology"},{"key":"12664_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.28313","volume":"36","author":"S Perez-Lloret","year":"2021","unstructured":"Perez-Lloret S, van de Warrenburg B, Rossi M et al (2021) Assessment of ataxia rating scales and cerebellar functional tests: critique and recommendations. Mov Disord 36:283\u2013297. https:\/\/doi.org\/10.1002\/mds.28313","journal-title":"Mov Disord"},{"key":"12664_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13162","author":"A Hamdan","year":"2024","unstructured":"Hamdan A, Hooker AC, Chen X et al (2024) Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias. CPT Pharmacomet Syst Pharmacol. https:\/\/doi.org\/10.1002\/psp4.13162","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"12664_CR5","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/mds.21544","volume":"22","author":"A Weyer","year":"2007","unstructured":"Weyer A, Abele M, Schmitz-H\u00fcbsch T et al (2007) Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord 22:1633\u20131637. https:\/\/doi.org\/10.1002\/mds.21544","journal-title":"Mov Disord"},{"key":"12664_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jns.2007.09.021","volume":"266","author":"I Yabe","year":"2008","unstructured":"Yabe I, Matsushima M, Soma H et al (2008) Usefulness of the scale for assessment and rating of ataxia (SARA). J Neurol Sci 266:164\u2013166. https:\/\/doi.org\/10.1016\/j.jns.2007.09.021","journal-title":"J Neurol Sci"},{"key":"12664_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneuro0426","volume":"3","author":"SH Subramony","year":"2007","unstructured":"Subramony SH (2007) SARA\u2013a new clinical scale for the assessment and rating of ataxia. Nat Clin Pract Neurol 3:136\u2013137. https:\/\/doi.org\/10.1038\/ncpneuro0426","journal-title":"Nat Clin Pract Neurol"},{"key":"12664_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s12311-022-01494-1","volume":"22","author":"MH Potashman","year":"2023","unstructured":"Potashman MH, Mize ML, Beiner MW et al (2023) Ataxia rating scales reflect patient experience: an examination of the relationship between clinician assessments of cerebellar ataxia and patient-reported outcomes. Cerebellum 22:1257\u20131273. https:\/\/doi.org\/10.1007\/s12311-022-01494-1","journal-title":"Cerebellum"},{"key":"12664_CR9","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1007\/s00415-021-10516-7","volume":"268","author":"RPPWM Maas","year":"2021","unstructured":"Maas RPPWM, Killaars S, van de Warrenburg BPC, Schutter DJLG (2021) The cerebellar cognitive affective syndrome scale reveals early neuropsychological deficits in SCA3 patients. J Neurol 268:3456\u20133466. https:\/\/doi.org\/10.1007\/s00415-021-10516-7","journal-title":"J Neurol"},{"key":"12664_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/mds.29255","volume":"38","author":"P Moulaire","year":"2023","unstructured":"Moulaire P, Poulet PE, Petit E et al (2023) Temporal dynamics of the scale for the assessment and rating of ataxia in spinocerebellar ataxias. Mov Disord 38:35\u201344. https:\/\/doi.org\/10.1002\/mds.29255","journal-title":"Mov Disord"},{"key":"12664_CR11","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","volume":"269","author":"T Bremova-Ertl","year":"2022","unstructured":"Bremova-Ertl T, Claassen J, Foltan T et al (2022) Efficacy and safety of N-acetyl-L-leucine in Niemann\u2013Pick disease type C. J Neurol 269:1651\u20131662. https:\/\/doi.org\/10.1007\/s00415-021-10717-0","journal-title":"J Neurol"},{"key":"12664_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl T, Ramaswami U, Brands M et al (2024) Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C. N Engl J Med 390:421\u2013431. https:\/\/doi.org\/10.1056\/NEJMoa2310151","journal-title":"N Engl J Med"},{"key":"12664_CR13","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","volume":"100","author":"K Martakis","year":"2023","unstructured":"Martakis K, Claassen J, Gascon-Bayari J et al (2023) Efficacy and safety of N-Acetyl-l-Leucine in children and adults with GM2 gangliosidoses. Neurology 100:e1072\u2013e1083. https:\/\/doi.org\/10.1212\/WNL.0000000000201660","journal-title":"Neurology"},{"key":"12664_CR14","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s00381-021-05246-0","volume":"37","author":"H Hartley","year":"2021","unstructured":"Hartley H, Lane S, Pizer B et al (2021) Ataxia and mobility in children following surgical resection of posterior fossa tumour: a longitudinal cohort study. Childs Nerv Syst 37:2831\u20132838. https:\/\/doi.org\/10.1007\/s00381-021-05246-0","journal-title":"Childs Nerv Syst"},{"key":"12664_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13063-020-05009-3","volume":"22","author":"T Fields","year":"2021","unstructured":"Fields T, Patterson M, Bremova-Ertl T et al (2021) A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann\u2013Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials 22:84. https:\/\/doi.org\/10.1186\/s13063-020-05009-3","journal-title":"Trials"},{"key":"12664_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13063-023-07399-6","volume":"24","author":"T Fields","year":"2023","unstructured":"Fields T, Bremova TM, Billington I et al (2023) N-acetyl-L-leucine for Niemann\u2013Pick type C: a multinational double-blind randomized placebo-controlled crossover study. Trials 24:361. https:\/\/doi.org\/10.1186\/s13063-023-07399-6","journal-title":"Trials"},{"key":"12664_CR17","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4:28\u201337","journal-title":"Psychiatry"},{"key":"12664_CR18","unstructured":"FDA (2023) Draft guidance for industry patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. Accessed 17 Jul 2024"},{"key":"12664_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/a:1015291021312","volume":"11","author":"N Aaronson","year":"2002","unstructured":"Aaronson N, Alonso J, Burnam A et al (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11:193\u2013205. https:\/\/doi.org\/10.1023\/a:1015291021312","journal-title":"Qual Life Res"},{"key":"12664_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S0767399X00003783","volume":"5","author":"JD Guelfi","year":"1990","unstructured":"Guelfi JD (1990) Clinical research in psychopharmacology: new standards for drug development. An application to antidepressants. Psychiatr Psychobiol 5:289\u2013294. https:\/\/doi.org\/10.1017\/S0767399X00003783","journal-title":"Psychiatr Psychobiol"},{"key":"12664_CR21","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5:1315\u20131316. https:\/\/doi.org\/10.1097\/JTO.0b013e3181ec173d","journal-title":"J Thorac Oncol"},{"key":"12664_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1176\/jnp.16.3.367","volume":"16","author":"JD Schmahmann","year":"2004","unstructured":"Schmahmann JD (2004) Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatr Clin Neurosci 16:367\u2013378. https:\/\/doi.org\/10.1176\/jnp.16.3.367","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"12664_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2183\/pjab.94.019","volume":"94","author":"N Yanagisawa","year":"2018","unstructured":"Yanagisawa N (2018) Functions and dysfunctions of the basal ganglia in humans. Proc Jpn Acad Ser B Phys Biol Sci 94:275\u2013304. https:\/\/doi.org\/10.2183\/pjab.94.019","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"12664_CR24","volume-title":"Neuroanatomy, pyramidal tract lesions","author":"A Lohia","year":"2024","unstructured":"Lohia A, McKenzie J (2024) Neuroanatomy, pyramidal tract lesions. StatPearls Publishing, Treasure Island"},{"key":"12664_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13054-019-2718-9","volume":"24","author":"S Benghanem","year":"2020","unstructured":"Benghanem S, Mazeraud A, Azabou E et al (2020) Brainstem dysfunction in critically ill patients. Crit Care 24:5. https:\/\/doi.org\/10.1186\/s13054-019-2718-9","journal-title":"Crit Care"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12664-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T23:54:49Z","timestamp":1727913289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["12664"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12664-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.19.24310680","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Bremova-Ertl received honoraria for lecturing from Sanofi and Acetlion and fees from IntraBio to serve as a blinded rater for the IB1001-201 and IB1001-202 clinical trials. P. Gissen received consulting fees from Mandos Health and is the Co-Founder and shareholder of Bloomsbury Genetic Therapies. M. Patterson is a shareholder in IntraBio and his institution has received research grants from Azafaros, Glycomine, Idorsia, Maggie\u2019s Pearl, Takeda, and Zevra, and consulting fees (directed to his institution) from Zevra. U. Ramaswami has received research and\/or investigator-initiated research grants from Amicus and Takeda and honoraria for advisory boards and lectures from Amicus, Takeda, and Sanofi. All other authors. The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}